Removal of intrahepatic bile duct stone could reduce the risk of cholangiocarcinoma: A single-center retrospective study in South Korea  

作　　者：Tae In Kim Sung Yong Han Jonghyun Lee Dong Uk Kim 

机构地区：[1]Division of Gastroenterology,Biomedical Research Institute,Pusan National University Hospital,Busan 49241,South Korea [2]Department of Internal Medicine,Pusan National University,College of Medicine,Yangsan 50612,South Korea

出　　处：《World Journal of Clinical Cases》2024年第5期913-921,共9页世界临床病例杂志

基　　金：Supported by a grant from the National R&D Program for Cancer Control,Ministry of Health and Welfare,Republic of Korea,No.HA20C0009.

摘　　要：BACKGROUND Intrahepatic duct(IHD)stones are among the most important risk factors for cholangiocarcinoma(CCC).Approximately 10%of patients with IHD stones develop CCC;however,there are limited studies regarding the effect of IHD stone removal on CCC development.AIM To investigate the association between IHD stone removal and CCC development.METHODS We retrospectively analyzed 397 patients with IHD stones at a tertiary referral center between January 2011 and December 2020.RESULTS CCC occurred in 36 of the 397 enrolled patients.In univariate analysis,chronic hepatitis B infection(11.1%vs 3.0%,P=0.03),carbohydrate antigen 19-9(CA19-9,176.00 vs 11.96 II/mL,P=0.010),stone located in left or both lobes(86.1%vs 70.1%,P=0.042),focal atrophy(52.8%vs 26.9%,P=0.001),duct stricture(47.2%vs 24.9%,P=0.004),and removal status of IHD stone(33.3%vs 63.2%,P<0.001)were significantly different between IHD stone patients with and without CCC.In the multivariate analysis,CA19-9>upper normal limit,carcinoembryonic antigen>upper normal limit,stones located in the left or both lobes,focal atrophy,and complete removal of IHD stones without recurrence were independent factors influencing CCC development.However,the type of removal method was not associated with CCC risk.CONCLUSION Complete removal of IHD stones without recurrence could reduce CCC risk.

关 键 词：Intrahepatic bile duct stone CHOLANGIOCARCINOMA Percutaneous transhepatic cholangioscopy Endoscopic retrograde cholangiopancreatography Carbohydrate antigen 19-9 

分 类 号：R735.8[医药卫生—肿瘤]